Emergence Therapeutics AG

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Eli Lilly and Company continued a year of strategic bolt-on acquisitions on 3 October with the planned buyout of the radiopharmaceutical company POINT Biopharma Global Inc. , with a tender offer tha

Looking to catch up with Novo Nordisk A/S and stay competitive in the burgeoning obesity/weight-loss therapy space, Eli Lilly and Company agreed to pay up to $1.925bn on 14 July for privately held

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. PhoreMost To Deploy SITESEEKER Platform